Clinical trials: Graft-vs-host Disease
Graft-Versus-Host Disease
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplant.
- Trial name
- NCT00201799
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human…
- Conditions
- Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00406393
- Testing
- Tacrolimus, Methotrexate, Sirolimus
- Where
- 24 sites in United States, France
- Volunteers
- 304 people
- Sponsor
- Medical College of Wisconsin
Low Back Pain
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients…
- Trial name
- NCT00246155
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ipsen
Acute Graft-versus-host Disease
Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation
Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell transplantation is one of the meaningful issues in aspect of patient's recovery and survival.
- Trial name
- CHIP-SCT (NCT02044185)
- Testing
- salvage chemotherapy, total body irradiation
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul St. Mary's Hospital
GVHD, Hematologic Neoplasms
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host…
- Trial name
- NCT03680092
- Testing
- Cyclophosphamide, abatacept, Methotrexate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Dimitrios Tzachanis, MD PhD
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in patients with different risk of GVHD.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT02294552
- Testing
- Cyclophosphamide, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Ivan S Moiseev
Bone Marrow Transplantation, Graft vs Host Disease
Toward Immune Biomarkers for Tolerance and GvHD in Humans
Graft-versus-Host Disease (GVHD), is the most frequent and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Bone Marrow Transplantation, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Trial name
- BioGvHD (NCT02319226)
- Testing
- Transplantation from an HLA-identical sibling donor
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Neoplasm, Graft-Versus-Host Disease
The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation
The allogenic stem cell transplantation (aSCT), the only curative approach for many hematological diseases, often leads to severe diseases or chronic conditions, leaving patients with physical disabilities and severe depression…
- Conditions
- Hematological Neoplasm, Graft-Versus-Host Disease, Depression, Stem Cell Transplant Complications
- Trial name
- TriCAM (NCT02976558)
- Testing
- Clown theatrical Performance, Acupuncture, Music Therapy TaKeTiNa
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Motor Stroke, Chronic
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.
- Trial name
- NCT03296618
- Testing
- NSI-566
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Neuralstem Biopharmaceuticals
Graft Vs Host Disease, Transplant Failure
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
The goal of this retrospective observational study is to investigate any possible association among tacrolimus (TAC) blood concentrations, clinical efficacy and tolerability.
- Conditions
- Graft Vs Host Disease, Transplant Failure, Stem Cell Transplant Complications
- Trial name
- NCT06080490
- Testing
- TAC C/D ratio
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- University of Pisa
Chronic Neck Pain
Multimodal Manual Therapy vs. Maitland Mobilization for Chronic Non-Specific Neck Pain
Chronic non-specific neck pain (CNNP) is a common musculoskeletal disorder associated with persistent pain, functional disability, and reduced quality of life.
- Trial name
- NCT07912099
- Testing
- Maitland Mobilization Treatment Approach, Manual therapy protocol
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- University of Management and Technology Lahore
Healthy, Lupus
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
This study aims to help researchers better understand health conditions and develop improved tests, treatments, and cures for diseases.
- Conditions
- Healthy, Lupus, Celiac, Kidney Disease
- Trial name
- JBMR (NCT07128966)
- Testing
- Observation
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Joined Bio
Graft Versus Host Disease
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
This pilot clinical trial studies romidepsin in treating patients with graft-versus-host disease (GVHD) that has not responded to treatment with steroids.
- Trial name
- NCT02203578
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Lymphoblastic, Chronic
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in patients with lymphoblastic acute leukemia who have been already treated with other therapies.
- Trial name
- NCT02388048
- Testing
- Ibrutinib + ofatumumab
- Where
- 35 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematologic Malignancies
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
The purpose of this study is to determine if Velcade (also known as bortezomib) can help prevent graft versus host disease (GVHD) developing after transplantation.
- Trial name
- NCT00369226
- Testing
- Bortezomib (Velcade), Tacrolimus, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD)…
- Trial name
- NCT03225417
- Testing
- Ixazomib, Tacrolimus, Sirolimus
- Where
- 8 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.